U.S. researchers said on Friday they plan to expand the size of a major study to determine the heart benefits of the controversial cholesterol fighter Vytorin, which they said would delay results until 2012.
Vytorin combines the statin Zocor, known generically as simvastatin with another cholesterol medicine, Zetia or ezetimibe, and is marketed by a joint venture of Merck & Co and Schering-Plough Corp....
Reuters - Mar 28, 2008
http://www.reuters.com/article/healthNews/idUSN2834981720080329?feedType=RSS&feedName=healthNews
